Loading
Life sciences · Journal article
BMC Cancer · October 30, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Reliable blood-based biomarkers that predict response to immune checkpoint inhibitor (ICI)–containing neoadjuvant chemotherapy (NAC) in patients with triple-negative breast cancer (TNBC) remain limited. CX3C chemokine receptor 1 (CX3CR1) expression on CD8⁺ T cells has emerged as a dynamic biomarker of response to ICI therapy in non–small cell lung cancer; however, its utility in TNBC remains unclear. We investigated whether dynamic changes in peripheral blood (PB) CX3CR1⁺ CD8⁺ T cells are associated with response to pembrolizumab-containing NAC in patients with TNBC. Serial PB samples were collected from 12 patients with early-stage TNBC undergoing pembrolizumab-containing NAC. The frequency of CX3CR1⁺ cells among CD8⁺ T cells was analyzed by flow cytometry before and during treatment. Associations between CX3CR1⁺ CD8⁺ T cell dynamics and tumor shrinkage, pathological complete response (pCR), and immune-related adverse events (irAEs) were evaluated. Baseline frequencies of CX3CR1⁺ CD8⁺ T cells were not associated with pCR. However, dynamic changes in CX3CR1⁺ CD8⁺ T cells were moderately correlated with tumor shrinkage ( r = 0.58, p = 0.04), whereas changes in absolute lymphocyte count showed no such association ( r = − 0.07, p = 0.82). All patients who achieved pCR exhibited ≥ 20% increase in CX3CR1⁺ CD8⁺ T cells during treatment at least once, compared with only one of seven patients who did not achieve pCR. No statistically significant association between treatment-induced changes in the frequency of CX3CR1⁺ CD8⁺ T cells and the occurrence of grade 3 irAEs was observed in this small cohort ( p = 0.99). Dynamic increases in PB CX3CR1⁺ CD8⁺ T cells during pembrolizumab-containing NAC were associated with treatment response in patients with TNBC, suggesting that CX3CR1 dynamics may serve as a blood-based marker of on-treatment response.